CA3103035A1 - Medication for inhibiting dna-pkcs - Google Patents

Medication for inhibiting dna-pkcs Download PDF

Info

Publication number
CA3103035A1
CA3103035A1 CA3103035A CA3103035A CA3103035A1 CA 3103035 A1 CA3103035 A1 CA 3103035A1 CA 3103035 A CA3103035 A CA 3103035A CA 3103035 A CA3103035 A CA 3103035A CA 3103035 A1 CA3103035 A1 CA 3103035A1
Authority
CA
Canada
Prior art keywords
endostatin
tumor
cell
cancer
natural human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3103035A
Other languages
English (en)
French (fr)
Inventor
Yongzhang Luo
Lin JIA
Guodong Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Publication of CA3103035A1 publication Critical patent/CA3103035A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3103035A 2017-07-30 2018-07-27 Medication for inhibiting dna-pkcs Pending CA3103035A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710638033.2 2017-07-30
CN201710638033 2017-07-30
CN201710733900 2017-08-24
CN201710733900.0 2017-08-24
PCT/CN2018/097609 WO2019024814A1 (zh) 2017-07-30 2018-07-27 抑制dna依赖蛋白激酶催化亚基的药物

Publications (1)

Publication Number Publication Date
CA3103035A1 true CA3103035A1 (en) 2019-02-07

Family

ID=65233426

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3103035A Pending CA3103035A1 (en) 2017-07-30 2018-07-27 Medication for inhibiting dna-pkcs

Country Status (7)

Country Link
US (2) US20200237796A1 (https=)
EP (1) EP3662922B1 (https=)
JP (1) JP7492687B2 (https=)
CN (1) CN110913884B (https=)
AU (1) AU2018310410B2 (https=)
CA (1) CA3103035A1 (https=)
WO (1) WO2019024814A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762615B2 (en) 1998-06-15 2003-07-03 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
CA2332179C (en) 1998-06-30 2011-06-28 Sloan-Kettering Institute For Cancer Research Uses of dna-pk
US7470667B2 (en) * 2002-12-05 2008-12-30 Medgenn (Hong Kong) Ltd Methods of treating cancer using a modified endostatin protein
US7078485B2 (en) 2002-12-05 2006-07-18 Yantai Medgenn Ltd. N-terminal modified recombinant human endostatin and its production
CN1891717A (zh) * 2005-07-08 2007-01-10 南京大学 内皮抑素的化学修饰方法及其应用
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN102698270B (zh) 2011-03-28 2016-02-03 清华大学 一种增强靶细胞摄取治疗剂的方法和药物组合物
CN108291248B (zh) 2011-09-09 2024-03-08 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体

Also Published As

Publication number Publication date
US20240165140A1 (en) 2024-05-23
US20200237796A1 (en) 2020-07-30
CN110913884B (zh) 2023-06-06
AU2018310410A1 (en) 2020-03-12
EP3662922B1 (en) 2025-03-05
JP7492687B2 (ja) 2024-05-30
EP3662922A4 (en) 2021-04-07
CN110913884A (zh) 2020-03-24
AU2018310410B2 (en) 2024-11-14
EP3662922A1 (en) 2020-06-10
WO2019024814A1 (zh) 2019-02-07
JP2020528457A (ja) 2020-09-24

Similar Documents

Publication Publication Date Title
JP6956159B2 (ja) 腫瘍溶解性アデノウイルスによる脳癌の処置方法
Koutsioumpa et al. Cell surface nucleolin as a target for anti-cancer therapies
JP5965322B2 (ja) 抗転移療法におけるａｘｌシグナル伝達の阻害
US9074011B2 (en) Use of PTEN-long leader sequence for transmembrane delivery of molecules
JP2014169293A (ja) Ｓｐａｒｃ及びその使用方法
Babaei-Jadidi et al. Mast-cell tryptase release contributes to disease progression in lymphangioleiomyomatosis
WO2016061231A1 (en) Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
Song et al. RNA interference-mediated suppression of TNF-α converting enzyme as an alternative anti-TNF-α therapy for rheumatoid arthritis
US20240165140A1 (en) Medication for inhibiting dna-pkcs
US20170281710A1 (en) Use of inhibitors of binding between a par-1 receptor and its ligands for the treatment of glioma
WO2014096855A1 (en) Angiopoietin-2 specific tie2 receptor
WO2021150770A1 (en) Oncogenic trim37 is a targetable epigenetic driver of metastasis and links chemoresistance and metastatic fate in triple-negative breast cancer
ES2373151B1 (es) Uso de inhibidores de edg2 para el tratamiento de la artritis reumatoide.
WO2024245445A1 (zh) Malt1肿瘤抑制剂、含有其的药物及应用
Sanders Modulation of the Immune Response as a Potential Therapeutic for Glioblastoma
Greene et al. Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers. Cells 2023, 12, 581
Koutsioumpa et al. Targeting Cell Surface Nucleolin in Cancer
JP2024058472A (ja) 抗線維化剤、線維症治療用医薬組成物、抗線維化剤の製造方法および抗線維化方法
Winkles GrB-TWEAK: A Potential Novel Biologic for NSCLC Therapy
US20150258194A1 (en) Modulating transendothelial migration and recruitment of granulocytes by modulating c-met pathway
Luo et al. Stress-induced Premature Promotes Prostate Cancer Growth and Metastasis through Alteration of Microenvironment
Przystal Combination of anti-cancer drug therapy with targeted gene therapy against glioblastoma
Papadimitriou Cell surface nucleolin as a target for anti-cancer therapies
CA2799066A1 (en) Method for cancer therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220823

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240719

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240725

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240725

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250321

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250714

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250714

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250721

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250723

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250725

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250725